Visualitzant l d'Hebron Barcelona Hospital Campus

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

Carey, Lisa; Loirat, Delphine; Punie, Kevin; Dieras, Veronique; Dalenc, Florence; Cortés Castan, Javier; Bardia, Aditya (Nature Research, 2022-06-09)

Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Cortés Castan, Javier; Loirat, Delphine; Gómez Pardo, Patricia; Schmid, Peter; Rugo, Hope; Marmé, Frederik; Bardia, Aditya (American Society of Clinical Oncology, 2022-10-10)

Sacral nerve modulation for patients with fecal incontinence: long-term outcome and effects on sexual function

Brusciano, Luigi; Brillantino, Antonio; Marinello, Franco; Baeten, Coen IM; Digesu, Alex; Pellino, Gianluca (Springer, 2023-08)

Safer prescription of drugs: impact of the PREFASEG system to aid clinical decision-making in primary care in Catalonia

Pons‑Mesquida, M. Àngels; Oms Arias, Míriam; Diogène Fadini, Eduard; Figueras, Albert (BMC, 2021-12-15)

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

Tolaney, Sara M; Loirat, Delphine; Punie, Kevin; Hurvitz, Sara; Cortés Castan, Javier; Rugo, Hope; Bardia, Aditya (Breast Cancer Research Foundation, 2022-08-29)

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study

Santin, Alessandro; González-Martin, Antonio; Moore, Kathleen N; Oaknin Benzaquen, Ana Mazaltob; Romero, Ignacio; Vergote, Ignace (BMJ, 2023-04)

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Hollebecque, Antoine; Varghese, Anna; Borazanci, Erkut; Macarulla Mercadé, Teresa; Oh, Do-Youn; Melisi, Davide; Calvo, Emiliano (BMJ Publishing Group, 2021-03-09)

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

Oaknin Benzaquen, Ana Mazaltob; Gilbert, Lucy; Tinker, Anna V.; Mathews, Cara; Press, Joshua; Brown, Jubilee (BMJ, 2022-01)

Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study)

Los Arcos Bertiz, Ibai; Martin Gomez, M Teresa; Sacanell Lacasa, Judith; Berastegui Garcia, Cristina; Marquez Algaba, Ester; Nuvials Casals, Xavier; Deu Martín, María; Castells Fusté, Lluis; Moreso Mateos, Francesc; Gavaldà Santpau, Joan; Len Abad, Oscar; Monforte, Arnau; Bravo Masgoret, Carles; Campany-Herrero, David; Sempere González, Abiu (American Society for Microbiology, 2022-02-16)

Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada

Aznar Ruiz de Alegria, Maria Luisa; Marras, Theodore K; Elshal, Ahmed Said; Mehrabi, Mahtab; Brode, Sarah K (BMC, 2019-06-03)

Safety and efficacy of a new supplementation protocol in patients with cystic fibrosis and vitamin D deficiency

Mangas-Sánchez, Carmen; Garriga, María; Serrano-Nieto, María Juliana; GARCIA ROMERO, RUTH; Álvarez Beltran, Marina; Crehuá-Gaudiza, Elena (Elsevier, 2023-04)

Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis

Ramírez-Estrada, Sergio; Forero, Carlos G.; Gallego, Miguel; Cardinal-Fernandez, P; Ehrmann, Stephan; Rello Condomines, Jordi; Soriano, Joan B; Tejada Magraner, Sofia (MDPI, 2022-02-19)

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

Gilbert, Lucy; Oaknin Benzaquen, Ana Mazaltob; Matulonis, Ursula A.; Mantia-Smaldone, Gina M.; Lim, Peter; Castro, Cesar (Elsevier, 2023-03)

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

Naumann, R. Wendel; Hollebecque, Antoine; Meyer, Tim; Devlin, Michael-John; Oaknin Benzaquen, Ana Mazaltob; Kerger, Joseph (American Society of Clinical Oncology, 2019-11-01)

Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study

Stilgenbauer, Stephan; Bosch Albareda, Francesc; Ilhan, Osman; Kisro, Jens; Mahé, Béatrice; Mikuskova, Eva (Wiley, 2021-04)

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Griesinger, Frank; Thomas, M.; Baik, Christina; Tan, Daniel S. W.; Garralda Cabanas, Elena; Subbiah, Vivek; Curigliano, Giuseppe (Elsevier, 2022-11)

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

Salvador-Bofill, Javier; Moreno, Fernando; Rodriguez Sanchez, Cesar Augusto; Galve Calvo, Elena; HERNANDO MELIA, CRISTINA; Ciruelos, Eva ; Bellet Ezquerra, Meritxell (Elsevier, 2022-12)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Coles, Alasdair; Traboulsee, Anthony; Singer, Barry A; Pozzilli, Carlo; Oreja-Guevara, C.; Achiron, Anat; Montalban, Xavier (SAGE Publications, 2023-09-21)

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

Burchert, Andreas; SESQUES, Pierre; Fransecky, Lars; Rejeski, Kai; IACOBONI, GLORIA; Barba, Pere; Bücklein, Veit (American Society of Hematology, 2022-08-23)

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

Corominas Garcia, Júlia; Garriga, Carme; Prenafeta, Antoni; Moros, Alexandra; Cañete, Manuel; Barreiro, Antonio; Sans-Pola, Carla; Otero-Romero, Susana; Martínez-Gómez, Xavier (Elsevier, 2023-05)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant Vall d'Hebron Barcelona Hospital Campus - VH per títol

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Sacral nerve modulation for patients with fecal incontinence: long-term outcome and effects on sexual function

Safer prescription of drugs: impact of the PREFASEG system to aid clinical decision-making in primary care in Catalonia

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study)

Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada

Safety and efficacy of a new supplementation protocol in patients with cystic fibrosis and vitamin D deficiency

Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant Vall d'Hebron Barcelona Hospital Campus - VH per títol

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis ﻿

Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer ﻿

Sacral nerve modulation for patients with fecal incontinence: long-term outcome and effects on sexual function ﻿

Safer prescription of drugs: impact of the PREFASEG system to aid clinical decision-making in primary care in Catalonia ﻿

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer ﻿

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study ﻿

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer ﻿

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study ﻿

Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study) ﻿

Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada ﻿

Safety and efficacy of a new supplementation protocol in patients with cystic fibrosis and vitamin D deficiency ﻿

Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis ﻿

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer ﻿

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial ﻿

Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study ﻿

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial ﻿

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial ﻿

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study ﻿

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy ﻿

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Sacral nerve modulation for patients with fecal incontinence: long-term outcome and effects on sexual function

Safer prescription of drugs: impact of the PREFASEG system to aid clinical decision-making in primary care in Catalonia

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study)

Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada

Safety and efficacy of a new supplementation protocol in patients with cystic fibrosis and vitamin D deficiency

Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial